Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT05154994 |
| Title | Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma (RESOLVE) |
| Acronym | RESOLVE |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | Yes |
| Sponsors | University of Utah |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
CKB BOOST